The FDA recently finalized a rule that will reshape one of the most widely used identifiers in the pharmaceutical industry: the National Drug Code (NDC).
Through its final rule, “Revising the National Drug Code Format and Drug Label Barcode Requirements,” the agency confirmed that the current 10-digit NDC format will transition to a standardized 12-digit format. The change will apply to NDCs assigned by the FDA for human drugs, biological products, and animal drugs marketed in the United States.
For organizations across the pharmaceutical supply chain, this is not just a formatting update. It is a data infrastructure change that will touch systems, labels, regulatory filings, and operational workflows.
Why the Change is Happening
The driving force behind this change is straightforward: the industry is running out of labeler codes.
Under the current system, many labeler codes are limited to five digits, and the rapid growth of pharmaceutical products through COVID has brought the system closer to exhaustion. Expanding to a six-digit labeler segment allows the FDA to significantly expand the available identifier space and ensure the NDC system remains sustainable for decades to come.
The FDA’s new rule creates a uniform 12-digit structure:
6-digit labeler code – 4-digit product code – 2-digit package code
The goal is to standardize the format across the healthcare ecosystem, reduce formatting inconsistencies, and ensure the NDC system can support the growing number of drug products entering the market.
You can read more about the rule on the FDA’s website:
https://www.fda.gov/drugs/electronic-drug-registration-and-listing-system-edrls/national-drug-code-format
Key Dates Organizations Should Know
Although the transition is several years away, the timeline is already defined.
- Now through March 6, 2033: FDA continues assigning 10-digit NDCs
- March 7, 2033: FDA begins assigning 12-digit NDCs and converts existing 10-digit codes to the new format
- March 7, 2033 – March 6, 2036: A three-year transition period allows companies to update labels and exhaust existing packaging inventory
During this transition window, the FDA has indicated it does not intend to object to continued use of 10-digit NDCs on drug labels while companies work through updates.
A Regulatory Change That Feels Familiar
For those who remember the run-up to the Year 2000 Problem (Y2K), this transition may sound surprisingly familiar.
In the late 1990s, organizations around the world had to update software and databases because many systems stored years using two digits instead of four. If systems were not updated, the calendar change to 2000 could cause widespread data errors.
The move to a 12-digit NDC format presents a similar challenge in principle. Across the healthcare ecosystem, systems have been built around a 10-digit identifier for decades. That means databases, validation rules, integrations, analytics platforms, and regulatory workflows will all need to recognize and process the new format.
Just like Y2K, the real work will happen behind the scenes in data systems long before the regulatory deadline arrives.
The Real Challenge: Operational and System Impacts
Although the implementation timeline stretches nearly a decade into the future, the operational implications are significant.
NDCs are deeply embedded across the pharmaceutical ecosystem, including:
- ERP and supply chain management platforms
- Serialization and product identifier systems
- Drug databases and regulatory submission tools
- Labeling and packaging systems
- Healthcare billing and reimbursement platforms
- Data exchanges with distributors, pharmacies, and other trading partners
Updating one system is manageable. Ensuring every connected system understands and exchanges the new format correctly is where the complexity emerges. This is especially important when considering the number of external integrations many companies rely on across the drug supply chain.
The Takeaway for Industry Teams
The move to a 12-digit NDC format may appear administrative at first glance but in practice it represents a large-scale data transition for the pharmaceutical industry. Just as organizations learned during Y2K, the biggest risks rarely come from the rule itself. They come from the systems and integrations that quietly depend on the existing format.
With the deadline still years away, now is the time for regulatory, compliance, and IT teams to begin evaluating where NDCs live across their systems and how those systems communicate internally and with trading partners.
Because when an identifier sits at the center of the entire supply chain, changing its structure is never just a formatting update. It is a data ecosystem change.